Prior studies where GDNF was delivered through intraputamen infusion to Parkinson patients showed that that dose as high as 30 ug/day at successive 8-week intervals could be delivered without any systemic toxicity and minimal level of the protein detected in the blood [27]. The gene discussed is GDNF; the disease is Parkinsonism.